We refer to the Company’s announcements dated 19 August 2020, 24 August 2020, 27 August 2020, 2 September 2020, 23 September 2020 and 24 September 2020.  The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that our subsidiary, Solution Biologics Sdn Bhd (“SOLBIO”), had on 30 October 2020 received a Letter of Authorisation (“LOA”) from CanSino Biologics Inc. (“CanSino”, SHSE: 688185, HKEX:06185).

CanSino has authorized SOLBIO to develop the business in Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos and Brunei (“Territory”), for their Recombinant Novel Coronavirus Vaccine candidate (Ad5-nCoV) composed of an adenovirus type 5 vector (Bulk Product presentation) (“Bulk Product”), by working with the respective local partners, authorities and regulatory bodies in the Territory in order to prepare the market for the Bulk Product, so that the Product can be sold when it is approved.

Eventually, Malaysia will be the regional fill and finish hub for CanSino and supply the finished product to the Territory.

The LOA is valid for six (6) months with effective from 28 October 2020.

We attach a copy of the Company's Press Release for information.

This announcement is dated 30 October 2020.